Epidermal Growth Factor Receptor Egfr Inhibitors
Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecasts to 2030 - Global Analysis By Type (Monoclonal Antibodies (mAbs), Tyrosine Kinase Inhibitors (TKIs), Combination Therapies and Other Types), Drug Type, Mode of Administration, Distribution Channel, Application, End User and By Geography
According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $14.1 billion in 2024 and is expected to reach $31.4 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of medications that target the epidermal growth factor receptor, a protein found on the surface of cells. EGFR is involved in cell growth and division, and its overactivity is associated with the development and progression of certain types of cancer, particularly lung cancer and colorectal cancer. GFR inhibitors are used in the treatment of various cancers, either alone or in combination with other cancer therapies, such as chemotherapy or radiation therapy.
According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease.
Market Dynamics:
Driver:
Growing adoption of targeted therapies
The market is witnessing a surge in adoption of targeted therapies, reflecting an evolving treatment landscape. Targeted therapies offer precision in combating cancer by specifically targeting cancer cells, minimizing damage to healthy tissue. This paradigm shift is driven by advancements in research and development, alongside increasing understanding of molecular pathways driving cancer progression. With personalized treatment approaches gaining traction, the market is poised for substantial growth as it moves towards tailored therapies for individual patients.
Restraint:
Availability of alternative therapies
The market faces challenges in accommodating alternative therapies. Despite the effectiveness of EGFR inhibitors, alternative treatments like immunotherapy and targeted therapies pose competition. Additionally, resistance to EGFR inhibitors and adverse effects contribute to the complexity. Ensuring accessibility, affordability, and patient awareness of alternative therapies remain key hurdles. The market must adapt by integrating these therapies into treatment protocols and addressing patient-specific needs for optimal outcomes.
Opportunity:
Rising cancer rates
The market has seen a concerning trend of rising cancer rates. Despite advancements in treatment utilizing EGFR inhibitors, such as Erlotinib and Gefitinib, the incidence of cancer cases reliant on these therapies has increased. This may indicate either a growing prevalence of EGFR-driven cancers or potential resistance development in patients previously responsive to these drugs. Such trends underscore the need for continued research into cancer biology and the development of innovative therapeutic strategies.
Threat:
High cost of treatment
The market faces challenges due to high treatment costs, posing a barrier to accessibility for patients. Despite their efficacy in treating certain cancers, the financial burden associated with these inhibitors limits their widespread adoption. This cost factor underscores the need for collaborative efforts among stakeholders to develop more affordable options or explore avenues for subsidization to ensure equitable access to life-saving treatments.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the Market, causing disruptions in manufacturing, supply chains, and clinical trials. Lockdowns and restrictions hindered patient access to healthcare facilities, affecting diagnosis and treatment initiation. However, with the adoption of telemedicine and remote monitoring, some continuity was maintained. The market witnessed fluctuations in demand, with a shift towards prioritizing essential treatments. Despite challenges, ongoing research and development efforts persisted, aiming to address emerging needs and optimize therapeutic outcomes amidst the pandemic's challenges.
The combination therapies segment is expected to be the largest during the forecast period
The combination therapies segment is expected to be the largest during the forecast period. By targeting multiple pathways simultaneously, these therapies aim to enhance efficacy and overcome resistance mechanisms. Combinations of EGFR inhibitors with chemotherapy, immunotherapy, and other targeted agents are being explored, showing potential in various cancer types. Such approaches offer new avenues for personalized treatment regimens and may improve patient outcomes by addressing heterogeneous tumor profiles and adaptive resistance mechanisms.
The colorectal cancer segment is expected to have the highest CAGR during the forecast period
The colorectal cancer segment is expected to have the highest CAGR during the forecast period driven by advancements in targeted therapies. These inhibitors, such as cetuximab and panitumumab, have shown promising results in improving patient outcomes by inhibiting EGFR signaling pathways. With increasing prevalence of colorectal cancer globally, coupled with growing demand for personalized treatment approaches, the EGFR inhibitors market is poised for significant growth.
Region with largest share:
North America is projected to hold the largest market share during the forecast period driven by factors such as increasing cancer prevalence and advancements in targeted therapies. With a focus on precision medicine, these inhibitors play a crucial role in treating various cancers, including lung and colorectal cancer. Key players in the region continue to invest in research and development, aiming to introduce innovative therapies.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period. The region has witnessed a rise in the incidence of cancer, including lung cancer and colorectal cancer, which are often treated with EGFR inhibitors. Increasing awareness about cancer and the availability of screening programs have led to earlier detection of cancers, resulting in more patients being eligible for targeted therapies. Moreover, rising healthcare expenditure and awareness further bolster market growth, fostering a competitive landscape characterized by ongoing clinical trials and product launches.
Key players in the market
Some of the key players in Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc, Eli Lilly and Company, OSI Pharmaceuticals Inc, Johnson & Johnson, Genentech, Inc, Pfizer, AstraZeneca PLC, Bayer AG, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim and Regeneron Pharmaceuticals.
Key Developments:
In May 2023, Eli Lilly and Innovent Biologics, Inc. jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).
In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.
Types Covered:
• Monoclonal Antibodies (mAbs)
• Tyrosine Kinase Inhibitors (TKIs)
• Combination Therapies
• Other Types
Drug Types Covered:
• Erlotinib
• Cetuximab
• Gefitinib
• Osimertinib
• Afatinib
• Other Drug Types
Mode of Administration Covered:
• Oral
• Intravenous
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Applications Covered:
• Non-Small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Other Applications
End Users Covered:
• Hospitals
• Cancer Treatment Centers
• Academic & Research Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Epidermal Growth Factor Receptor (EGFR) Market, By Type
5.1 Introduction
5.2 Monoclonal Antibodies (mAbs)
5.3 Tyrosine Kinase Inhibitors (TKIs)
5.4 Combination Therapies
5.5 Other Types
6 Global Epidermal Growth Factor Receptor (EGFR) Market, By Drug Type
6.1 Introduction
6.2 Erlotinib
6.3 Cetuximab
6.4 Gefitinib
6.5 Osimertinib
6.6 Afatinib
6.7 Other Drug Types
7 Global Epidermal Growth Factor Receptor (EGFR) Market, By Mode of Administration
7.1 Introduction
7.2 Oral
7.3 Intravenous
8 Global Epidermal Growth Factor Receptor (EGFR) Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
9 Global Epidermal Growth Factor Receptor (EGFR) Market, By Application
9.1 Introduction
9.2 Non-Small Cell Lung Cancer (NSCLC)
9.3 Pancreatic Cancer
9.4 Colorectal Cancer
9.5 Head and Neck Cancer
9.6 Other Applications
10 Global Epidermal Growth Factor Receptor (EGFR) Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Cancer Treatment Centers
10.4 Academic & Research Institutes
10.5 Other End Users
11 Global Epidermal Growth Factor Receptor (EGFR) Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Novartis AG
13.2 F. Hoffmann-La Roche Ltd
13.3 Merck & Co.
13.4 Amgen Inc
13.5 Eli Lilly and Company
13.6 OSI Pharmaceuticals Inc
13.7 Johnson & Johnson
13.8 Genentech, Inc
13.9 Pfizer
13.10 AstraZeneca PLC
13.11 Bayer AG
13.12 AbbVie
13.13 Bristol Myers Squibb
13.14 Teva Pharmaceutical Industries
13.15 Takeda Pharmaceutical Company Limited
13.16 Boehringer Ingelheim
13.17 Regeneron Pharmaceuticals
List of Tables
1 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Region (2021-2030) ($MN)
2 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Type (2021-2030) ($MN)
3 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Monoclonal Antibodies (mAbs) (2021-2030) ($MN)
4 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Tyrosine Kinase Inhibitors (TKIs) (2021-2030) ($MN)
5 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Combination Therapies (2021-2030) ($MN)
6 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Types (2021-2030) ($MN)
7 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Drug Type (2021-2030) ($MN)
8 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Erlotinib (2021-2030) ($MN)
9 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Cetuximab (2021-2030) ($MN)
10 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Gefitinib (2021-2030) ($MN)
11 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Osimertinib (2021-2030) ($MN)
12 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Afatinib (2021-2030) ($MN)
13 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Drug Types (2021-2030) ($MN)
14 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Mode of Administration (2021-2030) ($MN)
15 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Oral (2021-2030) ($MN)
16 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Intravenous (2021-2030) ($MN)
17 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Distribution Channel (2021-2030) ($MN)
18 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
19 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
20 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Online Pharmacies (2021-2030) ($MN)
21 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Application (2021-2030) ($MN)
22 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Non-Small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
23 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
24 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
25 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Head and Neck Cancer (2021-2030) ($MN)
26 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Applications (2021-2030) ($MN)
27 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By End User (2021-2030) ($MN)
28 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Hospitals (2021-2030) ($MN)
29 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
30 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
31 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
